Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Flaxman, S. R., Bourne, R. R. A., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M. V., Das, A., Jonas, J. B., Keeffe, J., Kempen, J. H., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30393-5 · Cited by 3,477
Self-citationSteinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
Self-citationPrevalence and Control of Diabetes in Chinese Adults
Xu, Y. (2013) · JAMA · doi:10.1001/jama.2013.168118 · Cited by 2,703
Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045
Teo, Z. L., Tham, Y.-C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y., Lu, Y., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.027 · Cited by 2,420
Self-citationTing, D. S. W., Cheung, C. Y.-L., Lim, G., Tan, G. S. W., Quang, N. D., Gan, A., Hamzah, H., Garcia-Franco, R., San Yeo, I. Y., Lee, S. Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.18152 · Cited by 2,402
“Next, the following subsidiary analyses were performed: (1) the analyses were repeated excluding patients who appeared in both the SIDRP 2010-2013 training set and the primary validation set of SIDRP 2014-2015 (n = 6291 seen more than once in SIDRP), with the patient treated as having referable diabetic retinopathy if…”
MethodSelf-citationGenetics of diabetes mellitus and diabetes complications
Cole, J. B., & Florez, J. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0278-5 · Cited by 1,797
Artificial Intelligence and Deep Learning in Ophthalmology
Wang, Z., Keane, P. A., Chiang, M., Cheung, C. Y., Wong, T. Y., & Ting, D. S. W. (2022) · Artificial Intelligence in Medicine · doi:10.1007/978-3-030-64573-1_200 · Cited by 1,524
Self-citationEpidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
“Yau (2012) [3] Meta-analysis Global Overall 7.”
BackgroundSelf-citationThe Lancet Global Health Commission on Global Eye Health: vision beyond 2020
Burton, M. J., Ramke, J., Marques, A. P., Bourne, R. R. A., Congdon, N., Jones, I., Ah Tong, B. A. M., Arunga, S., Bachani, D., Bascaran, C., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30488-5 · Cited by 1,624
Self-citationArtificial intelligence and deep learning in ophthalmology
Ting, D. S. W., Pasquale, L. R., Peng, L., Campbell, J. P., Lee, A. Y., Raman, R., Tan, G. S. W., Schmetterer, L., Keane, P. A., & Wong, T. Y. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313173 · Cited by 1,554
Self-citationKatsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Bourne, R., Steinmetz, J. D., Flaxman, S., Briant, P. S., Taylor, H. R., Resnikoff, S., Casson, R. J., Abdoli, A., Abu-Gharbieh, E., Afshin, A., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30425-3 · Cited by 1,431
Self-citationWong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
“DA VINCI 176 Aflibercept 46 (11) NR 12 157”
Self-citationThe progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Kang, Q., & Yang, C. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101799 · Cited by 1,066
Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T. B., Schnell, O., Standl, E., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878371 · Cited by 1,009
“6%, comparing BP 140/90 or> 140/ 90mmHg).(31) Glycaemic control represents an effective treatment to slow the progression of DR: a meta-analysis of four randomised trials (Action to Control Cardiovascular Risk in Diabetes, Action in Diabetes and Vascular Disease, UKPDS and Veterans Affairs Diabetes Trial) demonstrated…”
BackgroundTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
“251) .”
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
Self-citationDiabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
“Likewise, hypertension has been linked to increased risk of DR (20), and some data indicate that patients may benefit from the use of antihypertensive agents (21).”
BackgroundDiabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
Introduction to artificial intelligence in medicine
Mintz, Y., & Brodie, R. (2019) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2019.1575882 · Cited by 784
“This condition affects the tiny blood vessels which supply the retina and may cause haemorrhage or retinal detachment, leading to reduced vision and blindness [42,43].”
BackgroundGuidelines on Diabetic Eye Care
Wong, T. Y., Sun, J., Kawasaki, R., Ruamviboonsuk, P., Gupta, N., Lansingh, V. C., Maia, M., Mathenge, W., Moreker, S., Muqit, M. M. K., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.007 · Cited by 839
Self-citationIntravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationMechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Diagnostic assessment of deep learning algorithms for diabetic retinopathy screening
Li, T., Gao, Y., Wang, K., Guo, S., Liu, H., & Kang, H. (2019) · Information Sciences · doi:10.1016/j.ins.2019.06.011 · Cited by 663
Leasher, J. L., Bourne, R. R. A., Flaxman, S. R., Jonas, J. B., Keeffe, J., Naidoo, K., Pesudovs, K., Price, H., White, R. A., Wong, T. Y., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2171 · Cited by 651
Self-citationScreening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
The changing face of diabetes complications
Gregg, E. W., Sattar, N., & Ali, M. K. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30010-9 · Cited by 612
The worldwide epidemic of diabetic retinopathy
Congdon, N., Zheng, Y., & He, M. (2012) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.100542 · Cited by 632
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective
Li, J.-P. O., Liu, H., Ting, D. S. J., Jeon, S., Chan, R. V. P., Kim, J. E., Sim, D. A., Thomas, P. B. M., Lin, H., Chen, Y., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100900 · Cited by 626
Self-citationNeurodegeneration in diabetic retinopathy: does it really matter?
Simó, R., Stitt, A. W., & Gardner, T. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4692-1 · Cited by 591
Microvascular Complications of Type 2 Diabetes Mellitus
Faselis, C., Katsimardou, A., Imprialos, K., Deligkaris, P., Kallistratos, M., & Dimitriadis, K. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161117666190502103733 · Cited by 549
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
“Globally, more than 100 million individuals are living with DR, and DR is a leading cause of blindness and visual impairment, especially among the working-age adult population (1, 3).”
BackgroundSelf-citationDiabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets
Das, A., McGuire, P. G., & Rangasamy, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.03.024 · Cited by 545
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Lu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517
“DR can lead to severe, permanent visual impairment and is the most common cause of blindness in working-age adults (8).”
BackgroundPrevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1168291 · Cited by 511
“Further, renal function sharply declined with increasing age (median [IQR] eGFR; <65 years: 86 [32] ml/min/1.”
BackgroundDiabetes in Asia and the Pacific: Implications for the Global Epidemic
Nanditha, A., Ma, R. C. W., Ramachandran, A., Snehalatha, C., Chan, J. C. N., Chia, K. S., Shaw, J. E., & Zimmet, P. Z. (2016) · Diabetes Care · doi:10.2337/dc15-1536 · Cited by 487
Self-citationIncidence and progression of diabetic retinopathy: a systematic review
Sabanayagam, C., Banu, R., Chee, M. L., Lee, R., Wang, Y. X., Tan, G., Jonas, J. B., Lamoureux, E. L., Cheng, C.-Y., Klein, B. E. K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30128-1 · Cited by 491
Self-citationNeurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 490
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism
Eid, S., Sas, K. M., Abcouwer, S. F., Feldman, E. L., Gardner, T. W., Pennathur, S., & Fort, P. E. (2019) · Diabetologia · doi:10.1007/s00125-019-4959-1 · Cited by 468
Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
Ding, J., & Wong, T. Y. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0283-6 · Cited by 439
Self-citationVascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 412
“In a pooled analysis of 35 studies of diabetic people, collected from 1980 to 2008 from around the world, the prevalence among those 20 to 79 years old was 35% for any retinopathy, 7% for proliferative retinopathy, and 10% for vision threatening retinopathy.(17) Patients of African or Caribbean descent have higher rat…”
BackgroundPrevalence of and Risk Factors for Diabetic Macular Edema in the United States
Varma, R., Bressler, N. M., Doan, Q. V., Gleeson, M., Danese, M., Bower, J. K., Selvin, E., Dolan, C., Fine, J., Colman, S., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2854 · Cited by 423
Self-citationBellemo, V., Lim, Z. W., Lim, G., Nguyen, Q. D., Xie, Y., Yip, M. Y. T., Hamzah, H., Ho, J., Lee, X. Q., Hsu, W., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30004-4 · Cited by 419
Self-citationSayres, R., Taly, A., Rahimy, E., Blumer, K., Coz, D., Hammel, N., Krause, J., Narayanaswamy, A., Rastegar, Z., Wu, D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.016 · Cited by 418
Machine Learning Methods to Predict Diabetes Complications
Dagliati, A., Marini, S., Sacchi, L., Cogni, G., Teliti, M., Tibollo, V., De Cata, P., Chiovato, L., & Bellazzi, R. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817706375 · Cited by 407
Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis
Shu, D. Y., & Lovicu, F. J. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.08.001 · Cited by 387
Thomas, R. L., Halim, S., Gurudas, S., Sivaprasad, S., & Owens, D. R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107840 · Cited by 379
Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. M., & Wong, T. Y. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 361
Self-citationChiu, S. J., Allingham, M. J., Mettu, P. S., Cousins, S. W., Izatt, J. A., & Farsiu, S. (2015) · Biomedical Optics Express · doi:10.1364/boe.6.001172 · Cited by 377
Artificial intelligence for diabetic retinopathy screening: a review
Grzybowski, A., Brona, P., Lim, G., Ruamviboonsuk, P., Tan, G. S. W., Abramoff, M., & Ting, D. S. W. (2020) · Eye · doi:10.1038/s41433-019-0566-0 · Cited by 376
“The prevalence of diabetic retinopathy (DR), a primary cause of blindness and vision loss worldwide, was estimated at 93 million in 2012—out of which 28 million people had vision-threatening DR—and this is also expected to further increase [2, 3].”
BackgroundBalaratnasingam, C., Inoue, M., Ahn, S., McCann, J., Dhrami-Gavazi, E., Yannuzzi, L. A., & Freund, K. B. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.008 · Cited by 367
Methods and algorithms for optical coherence tomography-based angiography: a review and comparison
Zhang, A., Zhang, Q., Chen, C.-L., & Wang, R. K. (2015) · Journal of Biomedical Optics · doi:10.1117/1.jbo.20.10.100901 · Cited by 371
“The DR is a leading cause of blindness in American adults.(78) The fluorescein angiogram of the patient was illustrated in Fig.”
BackgroundDiabetic retinopathy: hyperglycaemia, oxidative stress and beyond
Hammes, H.-P. (2018) · Diabetologia · doi:10.1007/s00125-017-4435-8 · Cited by 357
“The overall prevalence of diabetic retinopathy is 35% among people with diabetes worldwide, with a current decline in both any retinopathy and sight-threatening stages [1].”
BackgroundVEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes
Suryavanshi, S. V., & Kulkarni, Y. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00798 · Cited by 348
“Recent reports state that in 2010, one third of an estimated 285 million people with diabetes have signs of DR (Yau et al., 2012; Lee et al., 2015).”
BackgroundDeep learning for diabetic retinopathy detection and classification based on fundus images: A review
Tsiknakis, N., Theodoropoulos, D., Manikis, G., Ktistakis, E., Boutsora, O., Berto, A., Scarpa, F., Scarpa, A., Fotiadis, D. I., & Marias, K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104599 · Cited by 328
“It is the leading cause of blindness among working age adults around the world and it is estimated that there are approximately 93 million people with DR worldwide [4].”
BackgroundSong, P., Yu, J., Chan, K. Y., Theodoratou, E., & Rudan, I. (2018) · Journal of Global Health · doi:10.7189/jogh.08.010803 · Cited by 341
Bourne, R. R. A., Jonas, J. B., Flaxman, S. R., Keeffe, J., Leasher, J., Naidoo, K., Parodi, M. B., Pesudovs, K., Price, H., White, R. A., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304033 · Cited by 341
Self-citationThan, A., Liu, C., Chang, H., Duong, P. K., Cheung, C. M. G., Xu, C., Wang, X., & Chen, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06981-w · Cited by 345
Stöhr, J., Barbaresko, J., Neuenschwander, M., & Schlesinger, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-93062-6 · Cited by 287
“Studies were excluded, if (1) they were animal studies, cross-sectional studies, case–control studies, conference abstracts or reviews, (2) they only reported crude estimates, (3) the study population was not relevant (including pregnant women or children and adolescents), (4) they focused on hyperglycemia (Fasting pl…”
BackgroundOxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy
Kowluru, R. A., Kowluru, A., Mishra, M., & Kumar, B. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.05.001 · Cited by 333
“Systemic factors M AN US CR IP T AC CE PT ED 10 Cross-sectional and longitudinal studies have clearly documented that, in addition to sustained hyperglycemia, hypertension and dyslipidemia are also important factors in the development of diabetic retinopathy (Yau et al., 2012).”
Ullah, A., Anwar, S. M., Li, J., Nadeem, L., Mahmood, T., Rehman, A., & Saba, T. (2024) · Complex & Intelligent Systems · doi:10.1007/s40747-023-01175-4 · Cited by 263
“The performance of deep learning was very much better in detecting various health conditions such as brain tumor detection, tuberculosis from chest images [157, 158], breast cancer detection [159], and malignant melanoma on skin images [160].”
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
“57% in people with type 2 diabetes mellitus (T2DM) [3,4].”
BackgroundInfluentialBiomarkers in Diabetic Retinopathy
Jenkins, A. J., Joglekar, M. V., Hardikar, A. A., Keech, A. C., O'Neal, D. N., & Januszewski, A. S. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.159 · Cited by 296
Wong, T. Y., & Sabanayagam, C. (2020) · Ophthalmologica · doi:10.1159/000502387 · Cited by 310
Self-citationWorsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
Bain, S. C., Klufas, M. A., Ho, A., & Matthews, D. R. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13538 · Cited by 299
“ing long duration of diabetes, poor glycaemic control and poorly controlled hypertension.(2,3) Deterioration of DR, upon initiation of stringent diabetes treatment, is referred to as “early worsening”.”
BackgroundSemaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318
“Risk factors for the development and progression of diabetic retinopathy (DR) include poor glycaemic control, long duration of diabetes and poorly controlled blood pressure.(9) The beneficial effect of long-term, stringent glycaemic control on the prevention or delay in onset or progression of DR in patients with type…”
BackgroundMechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
“Studies have discovered that the coverage of pericytes is reduced by producing transgenic mouse strains, while inadequate pericyte coverage can lead to BRB damage and increased leakage of the developing retinal vascular system, thus impairing visual performance (250).”
BackgroundInfluentialPrevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries
Ruta, L. M., Magliano, D. J., LeMesurier, R., Taylor, H. R., Zimmet, P. Z., & Shaw, J. E. (2013) · Diabetic Medicine · doi:10.1111/dme.12119 · Cited by 311
Self-citationDeep Learning Techniques for Diabetic Retinopathy Classification: A Survey
Atwany, M. Z., Sahyoun, A. H., & Yaqub, M. (2022) · IEEE Access · doi:10.1109/access.2022.3157632 · Cited by 266
“The amount of time a patient is diabetic, high haemoglobin A1c and high blood pressure readings are considered to be the highest risk factors associated with the development of DR [5].”
BackgroundGillies, M. C., Lim, L. L., Campain, A., Quin, G. J., Salem, W., Li, J., Goodwin, S., Aroney, C., McAllister, I. L., & Fraser-Bell, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.002 · Cited by 301
van der Heijden, A. A., Abramoff, M. D., Verbraak, F., van Hecke, M. V., Liem, A., & Nijpels, G. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13613 · Cited by 296
“In 2012, the overall worldwide prevalence of any form of diabetic retinopathy (DR) was 35% (Yau et al. 2012).”
BackgroundEvaluating All Potential Oral Complications of Diabetes Mellitus
Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A., & Teeuw, W. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00056 · Cited by 276
“For example, damage to endothelial cells in the retina and kidney cause retinopathy (34, 35) and nephropathy (36, 37), respectively.”
BackgroundSahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Deep neural networks to predict diabetic retinopathy
Gadekallu, T. R., Khare, N., Bhattacharya, S., Singh, S., Maddikunta, P. K. R., & Srivastava, G. (2023) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-020-01963-7 · Cited by 283
“In the advanced stages, leakages from the blood vessels in the eyes cause serious vision problems even leading to blindness (Yau et al. 2012).”
BackgroundDiabetic retinopathy: pathogenesis, clinical grading, management and future developments
Heng, L. Z., Comyn, O., Peto, T., Tadros, C., Ng, E., Sivaprasad, S., & Hykin, P. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12089 · Cited by 285
Deep Learning for Diabetes: A Systematic Review
Zhu, T., Li, K., Herrero, P., & Georgiou, P. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3040225 · Cited by 264
“Diabetic retinopathy (DR) is the leading cause of vision impairments and blindness in the world [107].”
BackgroundXie, Y., Nguyen, Q. D., Hamzah, H., Lim, G., Bellemo, V., Gunasekeran, D. V., Yip, M. Y. T., Qi Lee, X., Hsu, W., Li Lee, M., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30060-1 · Cited by 288
Self-citationRed Lesion Detection Using Dynamic Shape Features for Diabetic Retinopathy Screening
Seoud, L., Hurtut, T., Chelbi, J., Cheriet, F., & Langlois, J. M. P. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2015.2509785 · Cited by 277
“One out of three diabetic person presents signs of DR [2] and one out of ten suffers from its most severe and vision-threatening forms [3].”
BackgroundLee, J., Moon, B. G., Cho, A. R., & Yoon, Y. H. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.010 · Cited by 280
Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R. R., Wang, X., & Michelessi, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008081.pub3 · Cited by 265
Artificial Intelligence With Deep Learning Technology Looks Into Diabetic Retinopathy Screening
Wong, T. Y., & Bressler, N. M. (2016) · JAMA · doi:10.1001/jama.2016.17563 · Cited by 271
Self-citationGlycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
Kidney and eye diseases: Common risk factors, etiological mechanisms, and pathways
Wong, C. W., Wong, T. Y., Cheng, C.-Y., & Sabanayagam, C. (2014) · Kidney International · doi:10.1038/ki.2013.491 · Cited by 276
Self-citationZur, D., Iglicki, M., Busch, C., Invernizzi, A., Mariussi, M., Loewenstein, A., Busch, C., Cebeci, Z., Chhablani, J. K., Chaikitmongkol, V., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.031 · Cited by 271
“The GEE models for outcome measures (BCVA response at 2 and 4 months) were run by testing the following predictors at baseline: (1) BCVA; (2) naïve or refractory DME; (3) the presence of SRF; (4) the presence of ONL cysts; (5) ONL cyst size; (6) presence of INL cysts; (7) IS/OS continuity; (8) HRF presence; (9) HRF qu…”
BackgroundMethodInfluentialSafi, S. Z., Qvist, R., Kumar, S., Batumalaie, K., & Ismail, I. S. B. (2014) · BioMed Research International · doi:10.1155/2014/801269 · Cited by 257
“Globally, there are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR [4].”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
Tamayo, T., Rosenbauer, J., Wild, S. H., Spijkerman, A. M. W., Baan, C., Forouhi, N. G., Herder, C., & Rathmann, W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.007 · Cited by 247
Tan, J. H., Fujita, H., Sivaprasad, S., Bhandary, S. V., Rao, A. K., Chua, K. C., & Acharya, U. R. (2017) · Information Sciences · doi:10.1016/j.ins.2017.08.050 · Cited by 266
“It affects more than one third of people with diabetes, estimated at more than 95 million people globally [16,37].”
BackgroundDehdashtian, E., Mehrzadi, S., Yousefi, B., Hosseinzadeh, A., Reiter, R. J., Safa, M., Ghaznavi, H., & Naseripour, M. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.001 · Cited by 263
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub5 · Cited by 228
The Evolving Treatment of Diabetic Retinopathy
Mansour, S. E., Browning, D. J., Wong, K., Flynn Jr, H. W., & Bhavsar, A. R. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s236637 · Cited by 229
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.